Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma (IDARA)

  • STATUS
    Recruiting
  • End date
    Dec 31, 2025
  • participants needed
    70
  • sponsor
    University Hospital, Caen
Updated on 12 February 2022
vasectomy
cancer
calcium
hematologic malignancy
melphalan
prednisone
growth factor
bone marrow procedure
dexamethasone
lenalidomide
progressive disease
neutrophil count
bone lesion
bortezomib
serum calcium
daratumumab
refractory multiple myeloma
ixazomib
hypercalcemia
plasmacytoma

Summary

Multiple myeloma is an incurable hematological malignancy that affects older patients. Currently, despite recent progress, the disease relapses more or less quickly after initial treatment and requires the resumption of treatment with new drugs associated with cortisone, whose side effects are important. The investigators propose to conduct a phase 2 testing the combination ixazomib - daratumumab without dexamethasone.

Details
Condition Multiple Myeloma
Treatment Ixazomib and Daratumumab
Clinical Study IdentifierNCT03757221
SponsorUniversity Hospital, Caen
Last Modified on12 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Must be able to understand and voluntarily sign an informed consent form
Must be able to adhere to the study visit schedule and other protocol requirements
Age >= 65 years
Subjects affiliated with an appropriate social security system
Life expectancy > 6 months
Patients must have relapsed myeloma, and have been previously treated with Bortezomib, Melphalan and Prednisone (VMP) or Lenalidomide and Dexamethasone (Rd), or both
One or two line(s) of prior therapies
Patients must have Progressive Disease as defined by the IMWG as one of the following (Kumar, 2016): Increase of 25% from lowest response value in any one or more of the following
Serum M-component (absolute increase must be 0.5 g/100 ml) and/or Urine M-component (absolute increase must be 200 mg per 24 h) and/or
Only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels (absolute increase must be > 10 mg/l)
Bone marrow plasma cell percentage (absolute % must be 10%)
Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas
Development of hypercalcemia (corrected serum calcium > 11.5 mg/100 ml) that can be attributed solely to the plasma cell proliferative disorder
Patients must have undergone prior treatment with VMP or Rd
They must have received at least two cycles of therapy
Either at diagnosis or relapse
Patients must have a clearly detectable and quantifiable monoclonal M-component value: IgG (serum M-component > 10g/l) ; IgA (serum M-component > 5g/l) ; IgD (serum M-component > 0.5g/l); Light chain (serum M-component >1g/l or Bence Jones > 200 mg/24H) In patients without measurable serum and urine M-protein levels when the absolute serum Free Light chain (sFLC) is 100 mg/l and an abnormal sFLC K/ ratio (<0.26 and >1.65) is found (Dispenzieri, 2008)
Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
Adequate bone marrow function within 5 days prior to 1st drug intake (cycle1, day 1, C1D1), without transfusion nor growth factor support within 5 days prior to 1st drug intake, defined as: Absolute neutrophils 1000/mm3 ; Platelets 50000/mm3 ; Haemoglobin 8.5g/dl
Adequate organ function defined as: Serum creatinine clearance (MDRD formula) 30 ml/min ; Serum SGOT or SGPT < 3.0 X upper limit of normal (ULN) ; Serum total bilirubin < 1.5 ULN
Wash out period of at least 2 weeks from previous antitumor therapy or any investigational treatment or 5 half-lives from previous antibodies
Women who are partners of men and of childbearing potential must be practicing one of the following methods of birth control: subcutaneous hormonal implant, levonorgestrel releasing intra-uterine system, medroxyprogesterone acetate depot, tubal sterilization, ovulation inhibitory progesterone only pills, or sexual intercourse with a vasectomized male partner (vasectomy must be confirmed by 2 negative semen analyses). Or women will commit to absolute and continuous abstinence confirmed to her physician on a monthly basis. Childbearing potential. Contraception will start during therapy including dose interruptions, for 4 months after discontinuation of Ixazomib and Daratumumab
Criteria for women of childbearing potential
This protocol defines a female of childbearing potential as a sexually mature
woman who
has not undergone a hysterectomy or bilateral oophorectomy or
has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months)
A woman of childbearing potential must have 2 negative serum or urine pregnancy tests at Screening, first within 28 days prior to dosing and the second within 48 hours prior to dosing, and remain on a highly effective method of birth control. The two methods of reliable contraception must include one highly effective method and one additional effective (barrier) method. FCBP must be referred to a qualified provider of contraceptive methods if needed. The following are examples of highly effective and additional effective methods of contraception
Highly effective methods: Intrauterine device (IUD) ; Hormonal (birth control pills, injections, implants) ; Tubal ligation ; Partner's vasectomy
Additional effective methods: Male condom ; Diaphragm CervicalCap
Serum (urine in the case where serum is not possible in a timely manner) pregnancy test to be performed for all women of childbearing potential regularly during the study, In addition, a pregnancy test may be done at any time during the study at the discretion of the investigator if a subject misses a period or has unusual menstrual bleeding
A woman of childbearing potential must remain on a highly effective method of birth control. Contraception must begin 4 weeks before initiating treatment with Ixazomib and Daratumumab, during therapy, during dose interruptions and continuing for 4 months following discontinuation of Ixazomib and Daratumumab. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy
A man who has not had a vasectomy and who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control eg, condom with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study, for 4 months following discontinuation of Ixazomib and Daratumumab. The exception to this restriction is that if the subject's female partner is surgically sterile, a second method of birth control is not required

Exclusion Criteria

Target disease exceptions: Solitary bone/solitary extramedullary plasmocytoma ; Patients with non-secretory MM and non-measurable MM ; Evidence of central nervous system (CNS) involvement
Medical history and Concurrent disease
Subjects with prior ( 5 years) or concurrent invasive malignancies except the following: Adequately treated basal cell or squamous cell skin cancer ; Incidental finding of low grade (Gleason 3+3 or less) prostate cancer ; Any cancer from which the subject has been disease free for at least 3 years
Subject with known/underlying medical conditions that, in the investigator's opinion would make the administration of the study drug hazardous (ie: uncontrolled diabetes or uncontrolled coronary artery disease)
Any uncontrolled or severe cardiovascular or pulmonary disease determined by the investigator including: NYHA functional classification III or IV congestive heart failure LVEF (Left Ventricular Ejection Fraction) 45% ; Uncontrolled angina, hypertension or arrhythmia Myocardial infarction in the past 6 months
Subjects with grade 2 or greater peripheral neuropathy (as per NCI-CTCAEv4.0)
Subject is a woman who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 4 months after the last dose of any component of the treatment regimen. Or, subject is a man who plans to father a child while enrolled in this study or within 4 months after the last dose of any component of the treatment regimen
Known positive for HIV or active hepatitis B or C
Subjects with psychiatric illnesses or social situations that would preclude them understanding the informed consent, study compliance or the ability to tolerate study procedures and/or study therapy
Subjects with known chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) < 50% of predicted normal. Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 <50% of predicted normal
Subjects with a history of moderate or severe persistent asthma within the past 2 years (see appendix), or with uncontrolled asthma of any classification at the time of screening (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study)
Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of Ixazomib including difficulty swallowing
Physical and laboratory test findings
Patients on dialysis or with a Creatinine clearance < 30mL/min
SGOT or SGPT >3ULN
Prohibited prior therapies
Prior local irradiation within two weeks before first dose
Previous anti-CD38 therapy
Previous Ixazomib therapy
Allergies and Adverse Drug Reaction:Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
Refusal to consent or protected by a legal regime (guardianship, trusteeship)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note